公开(公告)号：US20230240549A1

公开(公告)日：2023-08-03

申请号：US18298414

申请日：2023-04-11

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Douglas Hettrick ,  Paul Coates

IPC: A61B5/027 ,  A61B18/14 ,  A61B5/0275 ,  A61B5/00

CPC classification number: A61B5/027 ,  A61B5/0275 ,  A61B5/4848 ,  A61B18/1492 ,  A61B2018/00404

Abstract: Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a blood flow rate through the renal blood vessel via the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the blood flow rate through the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline and post-neuromodulation measurements are obtained by injecting an indicator fluid into the renal blood vessel upstream of the target site and detecting a transient change in vessel impedance caused by the indicator fluid.

公开(公告)号：US11707220B2

公开(公告)日：2023-07-25

申请号：US16885574

申请日：2020-05-28

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Douglas Hettrick ,  Shantanu Sarkar

IPC: A61B5/00 ,  G16H50/30 ,  G16H50/20 ,  A61B5/0245 ,  A61N1/36 ,  A61B18/14 ,  G16H20/40 ,  G16H20/30 ,  A61B18/00 ,  A61B18/02 ,  A61B5/024 ,  A61B5/053 ,  A61N7/02 ,  A61B34/00 ,  G16H20/17 ,  A61B5/349

CPC classification number: A61B5/4035 ,  A61B5/0245 ,  A61B18/1492 ,  A61N1/36017 ,  G16H20/30 ,  G16H20/40 ,  G16H50/20 ,  G16H50/30 ,  A61B5/00 ,  A61B5/02405 ,  A61B5/053 ,  A61B5/349 ,  A61B5/4836 ,  A61B2018/00404 ,  A61B2018/00434 ,  A61B2018/00511 ,  A61B2018/00773 ,  A61B2018/00839 ,  A61B2018/00875 ,  A61B2018/0212 ,  A61B2018/0262 ,  A61B2018/1435 ,  A61B2034/256 ,  A61N7/022 ,  G16H20/17

Abstract: Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

公开(公告)号：US20230181251A1

公开(公告)日：2023-06-15

申请号：US18163615

申请日：2023-02-02

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Robert Melder ,  Martin Rothman ,  Stefan Tunev

IPC: A61B18/14

CPC classification number: A61B18/1492 ,  A61B2018/00214

Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, system, and methods are disclosed herein. One aspect of the present technology is directed to neuromodulating nerve tissue in selected anatomical regions. In one embodiment, the method can include intravascularly advancing an elongate shaft of a catheter to renal vasculature of a human patient and locating a first neuromodulation element of the catheter within a distalmost portion of a main renal artery. The method includes locating a second neuromodulation element of the catheter within a branch vessel of the renal artery distal to a bifurcation at a distal end of the main renal artery. Neuromodulation of the nerve tissue surrounding the selected anatomical treatment locations can inhibit sympathetic neural activity in nerves proximate a portion of a renal artery and/or a renal branch artery proximate a renal parenchyma.

公开(公告)号：US11464563B2

公开(公告)日：2022-10-11

申请号：US16983408

申请日：2020-08-03

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Brian Kelly ,  Micheál Moriarty

IPC: A61B18/14 ,  A61B18/00

Abstract: Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology, for example, is directed to a catheter apparatus including an elongated shaft defined by a braid embedded within a polymer. The braid can include one or more thermocouple assemblies intertwined with a braiding element. The thermocouple assemblies can be coupled to one or more electrodes at a distal portion of the shaft.

公开(公告)号：US20220296891A1

公开(公告)日：2022-09-22

申请号：US17717958

申请日：2022-04-11

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Ayala Hezi-Yamit ,  Rudy A. Beasley ,  Susan Thornton Edwards ,  Lori Garcia ,  Michele Lee Silver ,  Christopher W. Storment ,  Carol M. Sullivan ,  Joseph A. Traina ,  Stefan Stoyanov Tunev

IPC: A61N1/36 ,  A61N1/05 ,  A61B5/20 ,  A61B5/15 ,  A61B18/14 ,  A61B5/145 ,  A61B5/00

Abstract: Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers.

公开(公告)号：US20220241020A1

公开(公告)日：2022-08-04

申请号：US17727073

申请日：2022-04-22

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Douglas Hettrick ,  Julie Trudel

IPC: A61B34/10 ,  A61B5/02 ,  A61B5/0215 ,  A61B5/022 ,  A61B5/026 ,  A61B5/0538 ,  A61B5/055 ,  A61B5/00 ,  A61B6/03 ,  A61B6/00 ,  A61B8/06 ,  A61B8/08 ,  A61B18/02 ,  A61B18/14 ,  A61N1/05 ,  A61N1/36

Abstract: Methods and systems for optimizing perivascular neuromodulation therapy using computational fluid dynamics. Digital data regarding three-dimensional imaging of a target blood vessel and corresponding hemodynamic data are inputs to generating a computational fluid dynamics (CFD) model. The CFD model enables identification of one or more regions of the vessel suitable for neuromodulation therapy and/or identifying one or more regions of the vessel to avoid during such therapy. A system of the present technology can include a neuromodulation catheter, a computing device that can generate and analyze the CFD model, and a user interface for displaying the vessel with indicia for target regions and/or avoidance regions.

公开(公告)号：US11376398B2

公开(公告)日：2022-07-05

申请号：US17503866

申请日：2021-10-18

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Rudy Beasley ,  Justin Goshgarian ,  Vincent Ku

IPC: A61M25/00 ,  A61B18/14 ,  A61B17/32 ,  A61N1/05 ,  A61N1/06 ,  A61B18/00 ,  A61B18/02 ,  A61B18/06 ,  A61F7/00 ,  A61F7/12 ,  A61N7/00

Abstract: A neuromodulation catheter includes an elongate shaft and a neuromodulation element. The shaft includes two or more first cut shapes and two or more second cut shapes along a helical path extending around a longitudinal axis of the shaft. The first cut shapes are configured to at least partially resist deformation in response to longitudinal compression and tension on the shaft and torsion on the shaft in a first circumferential direction. The second cut shapes are configured to at least partially resist deformation in response to longitudinal compression on the shaft and torsion on the shaft in both first and second opposite circumferential directions.

公开(公告)号：US11350992B2

公开(公告)日：2022-06-07

申请号：US16944499

申请日：2020-07-31

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Garrett Pilcher ,  Robert Melder

IPC: A61B18/14 ,  A61N7/02 ,  A61N1/00 ,  A61N1/36 ,  A61B5/00 ,  A61N1/05 ,  A61N7/00 ,  A61B18/00 ,  A61B90/00 ,  A61B18/02 ,  A61B18/18 ,  A61B18/24

Abstract: Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

公开(公告)号：US20220096153A1

公开(公告)日：2022-03-31

申请号：US17494648

申请日：2021-10-05

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Martin Rothman ,  Paul Coates

IPC: A61B18/14 ,  A61B18/02 ,  G01R5/26

Abstract: Devices, systems, and methods for the selective positioning of an intravascular neuromodulation device are disclosed herein. Such systems can include, for example, an elongated shaft and a therapeutic assembly carried by a distal portion of the elongated shaft. The therapeutic assembly is configured for delivery within a blood vessel. The therapeutic assembly can include a pre-formed shape and can be transformable between a substantially straight delivery configuration; and a treatment configuration having the pre-formed helical shape to position the therapeutic assembly in stable contact with a wall of the body vessel. The therapeutic assembly can also include a mechanical decoupler operably connected to the therapeutic assembly that is configured to absorb at least a portion of a force exerted on the therapeutic assembly by the shaft so that the therapeutic assembly maintains a generally stationary position relative to the target site.

公开(公告)号：US20210386469A1

公开(公告)日：2021-12-16

申请号：US17461449

申请日：2021-08-30

Applicant: Medtronic Ardian Luxembourg S.a.r.l.

Inventor： Robert J. Melder

IPC: A61B18/06 ,  A61K9/00 ,  A61K31/165 ,  A61K47/64 ,  A61P25/00 ,  A61P13/12 ,  A61M37/00

Abstract: Devices, agents, and associated methods for selective modulation of renal nerves by localized delivery of neural ablative substances are disclosed herein. One aspect of the present technology is directed to a method for delivering a neuromodulatory agent (e.g., capsaicin) via a catheter to a kidney of the patient. The neuromodulatory agent selectively neuromodulates afferent renal nerves in a patient compared efferent renal nerves of the patient. The method can also include removing the catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.